title: Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks.
authors.forename: R
authors.initials: R
authors.lastname: Krishnan
authors.forename: D
authors.initials: D
authors.lastname: Cella
authors.forename: C
authors.initials: C
authors.lastname: Leonardi
authors.forename: K
authors.initials: K
authors.lastname: Papp
authors.forename: A B
authors.initials: AB
authors.lastname: Gottlieb
authors.forename: M
authors.initials: M
authors.lastname: Dunn
authors.forename: C F
authors.initials: CF
authors.lastname: Chiou
authors.forename: V
authors.initials: V
authors.lastname: Patel
authors.forename: A
authors.initials: A
authors.lastname: Jahreis
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D003866:Depressive Disorder / Q000188:drug therapy*; D004311:Double-Blind Method; D000068800:Etanercept; D005221:Fatigue / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D008297:Male; D011565:Psoriasis / Q000188:drug therapy* / Q000523:psychology; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept